Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Deal Watch: Gilead’s Move Into NASH Highlights Post-Holiday Deal-Making

Executive Summary

Amgen moves into the chimeric antigen receptor T-cell space in cancer under a complex partnership with Kite Pharma. Gilead, Isis and Janssen agree to multiple deals during and after the holiday season, while scuttled deals return assets or rights to Vanda, AMAG and OncoGenex.

You may also be interested in...



With 29 Candidates Advancing, NASH Race May Hinge On Long-Duration Data

Even with market estimates that NASH drugs eventually could command sales of $35 billion a year, some of the candidates and companies now competing in the space will have to be weeded out.

NASH Drugs Soon May Have A Registrational Pathway, Finally

Numerous companies vie to become first to market with a therapy for the unmet medical need, which can lead to fibrosis, cirrhosis and need for a liver transplant. FDA may allow surrogate endpoints in pivotal trials to speed up approval of initial NASH therapies.

NASH Opportunity Spurs Deal-Making Flurry

Companies big and small are making deals and advancing candidates to address an unmet medical need thought to have a vast undiagnosed patient base in the U.S. and Europe.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

PS056579

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel